Home 2022

MorphoSys

Two by 2025: MorphoSys Consolidates Research, Retains Commercialization Goal
Cancer

Two by 2025: MorphoSys Consolidates Research, Retains Commercialization Goal

Alex Philippidis -
0
GSK Advances Arthritis Candidate into Phase III, Triggering €22M Milestone Payment to MorphoSys
Industry News

GSK Advances Arthritis Candidate into Phase III, Triggering €22M Milestone Payment to MorphoSys

Alex Philippidis -
0
Top 10 Biopharma IPOs of January–June 2018
A-Lists

Top 10 Biopharma IPOs of January–June 2018

Alex Philippidis -
0
MorphoSys, Emergent to Develop Prostate Cancer Candidate
Cancer

MorphoSys, Emergent to Develop Prostate Cancer Candidate

GEN Staff Writer -
0
MorphoSys and BI Sign Process Development and Manufacturing Deal for CLL mAb
Bioprocessing

MorphoSys and BI Sign Process Development and Manufacturing Deal for CLL mAb

GEN Staff Writer -
0
MorphoSys and Proteros Get €850K to Develop Technology to Analyze Ab-Ag Complexes
Drug Discovery

MorphoSys and Proteros Get €850K to Develop Technology to Analyze Ab-Ag Complexes

GEN Staff Writer -
0
German Government Grants MorphoSys $1.26M to Progress Multiple Myeloma Antibody into Clinic
Cancer

German Government Grants MorphoSys $1.26M to Progress Multiple Myeloma Antibody into Clinic

GEN Staff Writer -
0
MorphoSys Nabs Xencor’s Phase I B-Cell Malignancy Antibody for $13M Up Front
Cancer

MorphoSys Nabs Xencor’s Phase I B-Cell Malignancy Antibody for $13M Up Front

GEN Staff Writer -
0
MorphoSys and Galapagos to Co-develop Therapeutic Antibodies in Bone and Joint Disease
News

MorphoSys and Galapagos to Co-develop Therapeutic Antibodies in Bone and Joint Disease

GEN Staff Writer -
0
DSM to Manufacture MorphoSys’ Multiple Myeloma Drug Candidate
News

DSM to Manufacture MorphoSys’ Multiple Myeloma Drug Candidate

GEN Staff Writer -
0
12Page 1 of 2
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.